FDA Finalizes Guidance on Co-Crystals in NDAs and ANDAs Post author:Sam Post published:February 14, 2018 Post category:Drug Industry Daily The FDA finalized new guidance establishing co-crystals as a drug product intermediate. Source: Drug Industry Daily You Might Also Like NICE to Recommend Kadcyla, Kyprolis for NHS Funding; But Rejects Besponsa Coverage Before EU Approval June 15, 2017 Califf Defends FDA Decisions, Calls for Improved Research System August 24, 2022 FDA Got Creative with Inspections During Pandemic, Plans to Stay That Way November 16, 2021
NICE to Recommend Kadcyla, Kyprolis for NHS Funding; But Rejects Besponsa Coverage Before EU Approval June 15, 2017